Technology
Health
Biotechnology

Zafgen

$2.98
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.01 (0.34%) Today
+$0.01 (0.34%) Today

Why Robinhood?

You can buy or sell Zafgen and other stocks, options, ETFs, and crypto commission-free!

About

Zafgen, Inc. Common Stock, also called Zafgen, is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. Read More It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

Employees
38
Headquarters
Boston, Massachusetts
Founded
2005
Market Cap
110.74M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
305.09K
High Today
$3.02
Low Today
$2.92
Open Price
$2.97
Volume
108.74K
52 Week High
$12.36
52 Week Low
$2.78

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Therapy
Utilities
Pharmaceutical
2014 IPO

News

Associated PressMar 15

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, Inc. Investors

This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. BENSALEM, Pa.--(BUSINESS WIRE)--Mar 15, 2019--Law Offices of Howard G. Smith announces an investigation on behalf of Zafgen, Inc. investors (“Zafgen” or the “Company”) (NASDAQ: ZFGN ) concerning the Company and its officers’ pos...

119
Seeking AlphaMar 14

Zafgen: Will There Be A Third Act?

Most observers wondered if that would be the end of the company - things like this have most certainly ended small biopharma companies before.

15
Associated PressMar 13

Zafgen to Present at the 31st Annual ROTH Conference

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. BOSTON, March 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected ...

29

Earnings

-$0.59
-$0.52
-$0.46
-$0.39
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.44 per share
Actual
-$0.39 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.